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The  value  of  new  cancer  drugs  is  maximized  when  they  are  used  for  the  right  patient  in  the right  way
in  clinical  practice.  Clinical  trials  conducted  during  drug  development  are  the  most  important  source
of  information  to predict  value  at the  time  a drug  is  introduced  in practice.  Regulatory  approval  is
an  indication  of  value,  which  lately  has  been  complemented  with  an  assessment  of clinical  value  for
decisions  about  reimbursement,  using  the  methodology  of health  technology  assessment  (HTA).  Formal
cost-effectiveness  studies  are  an  important  part  of  this  methodology,  aiming  to  assist  decisions  about
value  for money  in  health  care  spending.  The  question  is  if the  addition  of a complementary  HTA  and
cost-effectiveness  study  increases  the value  realized  by  the  drug  in  practice  compared  to how  it would
be  used  without  these  assessments.
We review  the  issues  involved  in  providing  an  answer  by  using  the introduction  of new  targeted
therapies  for metastatic  renal  cell  cancer  (mRCC).  Speciﬁcally,  we  examine  the  link  between  clinical trial
data  and  estimations  of  cost-effectiveness  at drug  launch,  reimbursement  decisions,  uptake  and  use  in
different  countries  and  evidence  about  impact  on  outcome  in patient  populations  for  which  the  new
drugs  are  indicated.
We conclude  that there  is  a  weak  link between  the  assessments  used  at drug  launch  and  the  value
created  in  clinical  practice.  We  suggest  measures  that are  necessary  for  the  achievement  of  evidence-
based  and  cost-effective  cancer  care  in  clinical  practice.
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Cost effectiveness studies are increasingly used for decisions
bout reimbursement and appropriate use of new cancer drugs.
hese studies thus affect access for patients and clinicians to treat-
ents that may  be of potential value, and direct the efﬁcient and
quitable use of health care resources for cancer.
While the general methodology of such studies is well devel-ped, and applied in a similar fashion in different jurisdictions, the
nterpretation and use of the ﬁndings differ. This is not surprising,
ince the relative value of a new medicine, reﬂected in willing-
ess as well as ability to pay for new treatment options, will differ
etween countries. This results in great variations in the use of
ew cancer drugs, and most striking is the impact of the per capita
ncome level on the uptake of new therapies [1].
 This paper is part of the Special Issue ‘Delivering Affordable Cancer Care in High
ncome Countries: Papers from a Special Session of Oncology At The Limits, 13th –
5th February 2014’.
∗ Corresponding author. Tel.: +46723985678.
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ttp://dx.doi.org/10.1016/j.jcpo.2014.02.001
213-5383 © 2014 The Authors. Published by Elsevier Ltd. Open access under CC BY-NC-ND lied  by Elsevier  Ltd.  
However, the variations in use of new cancer treatments cannot
be explained solely by differences in income levels and health care
spending. There is substantial variability in the use of new cancer
drugs between countries with similar income per capita. These dif-
ferences can to some extent be explained by differences in coverage
decisions [2].
But  decisions about coverage do not directly translate into
uptake and use of new cancer drugs. National institute for health
and care excellence (NICE) in the UK has made 151 individual rec-
ommendations on cancer drugs of which 57% have been positive [3].
Still, the actual use of cancer drugs in UK with NICE endorsements
is rather low, suggesting a disconnect between recommendations
and actual use [4]. The disconnect between coverage decisions is
also present in Sweden, where decisions by TLV, The Dental and
Pharmaceutical Beneﬁts Agency, is not directly linked to spending
in different county councils, resulting in great regional variations
in use of new cancer drugs [5].
Open access under CC BY-NC-ND license.This paper will review the link between clinical trial data, the
cost-effectiveness studies for new cancer drugs, coverage decisions
informed by such studies, uptake and use of the drugs, and evi-
dence of impact on outcome in the relevant patient population. The
cense.
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nclusion of impact on outcome in the analysis reﬂects the shift in
ocus from efﬁcacy to relative effectiveness in assessing the value
f new medicines [6]. Value for patients is created when anticancer
rugs are chosen that provide maximum difference in the chance
f beneﬁt and harm, the overall objective for personalized cancer
edicine [7]. The framework for the analysis is illustrated in Fig. 1.
Data from clinical trials is the key source for estimation of effec-
iveness in cost-effectiveness studies. Such studies are used to
nform decisions about reimbursement, which aim at guiding the
se of the drug in clinical practice. The use in clinical practice will
etermine outcome and thus the value of the drug. Use in clinical
ractice may  reveal evidence gaps that need new clinical trials to
e answered.
We  will use data from the introduction of newer targeted drugs
o treat mRCC to illustrate the methodological issues and data
eeds for assessing cost-effectiveness and impact on use and out-
ome. The paper will conclude with a discussion of the policy
mplications of the greater emphasis on relative effectiveness and
ost-effectiveness in clinical practice as a key goal for health policy.
enal cell carcinoma and new targeted therapies
Kidney cancer accounts for about 2–3 per cent of all cancers, and
he annual global incidence is about 340,000 cases. The incidence is
ighest in the US and Europe, and low in Africa and Asia. Renal cell
arcinoma accounts for about 80% of all kidney cancers. For local-
zed disease, which can be treated with surgery, the prognosis is
ood. For advanced or metastatic disease the 5 year survival rate
s only about 10%, and the annual number of deaths in kidney can-
er is 143,000, of which 53,000 is in Europe and 28,000 in the US.
ncidence and mortality is twice as high in men  as in women, and
aries with a factor three between countries in Europe [8].
A  number of targeted therapies for mRCC have been introduced
ince 2005 (Table 1).
Most  of the new treatments target tyrosine kinase pathways and
lock angiogenesis, the formation of new blood vessels, necessary
or tumour growth. The arrival of soraﬁnib and sunitinib in 2005–6
ollowed by other targeted drugs represents a major step forward
ompared to the previous standard treatment of interferon-alpha
nd interleukin-2. For patients with a good Karnofsky performance
tatus and intact organ function, high-dose interleukin-2 has often
een used in ﬁrst line because it can induce durable long-term
emissions in approximately 10 per cent of patients. The new drugs
ffered beneﬁts in terms of both oral administration and improved
utcome, but also potentially increased costs. The cost of treatment
ith the new targeted therapies are in the range of UKP 3–6000 perer Policy 2 (2014) 12–21 13
6 weeks, more than most patients can afford to pay. Decisions about
their use in clinical practice would thus beneﬁt from information
about cost-effectiveness [11].
Pazopanib was  approved 2009 in the US,  and got conditional
approval by EMA  in 2011 for ﬁrst line treatment. In a recent direct
comparison, pazopanib was shown to be non-inferior to sunitinib
[12]. Axitinib is the latest approval in 2012 for RCC, after failure of
prior systemic therapy with a cytokine or sunitinib.
The clinical trials and the decisions by FDA and EMA on market
authorization indicate survival beneﬁts from the use of the new,
targeted therapies. But since the primary clinical end-point in most
of the trials has been progression free survival (PFS), and patients
who fail on the comparator medicine (or placebo) cross over to the
evaluated drug, direct estimates of the magnitude of the overall
survival (OS) beneﬁt of these agents are lacking.
Cost-effectiveness studies of new therapies for mRCC
The  new, targeted therapies in mRCC are also interesting from
an economic perspective due to the challenges offered from their
pricing. The costs of therapy range from 5 to 10,000 USD per
month, and 100,000 USD or more over lifetime, have been a chal-
lenge for reimbursement agencies making recommendations on
coverage based on value for money, supported by estimates of
cost-effectiveness. This challenge has a methodological aspect, the
estimation of cost-effectiveness, and an ethical aspect, the trade-
off between equity and efﬁciency in making decisions based on
value.
Assessment of cost-effectiveness aims at producing estimates
of the likely costs and improvement in health from the use of
the drugs for deﬁned populations in clinical practice, compared
to the present standard of care. Results from clinical trials can
be used for modelling the likely consequences, but such predic-
tions will incorporate all the uncertainties in the clinical data as
well as uncertainty due to assumptions made in extrapolating
these data. Additional issues involved in modelling are the deﬁ-
nition of the relevant patient population and the relevant standard
of care for comparison, taking into account that the drugs will
be used differently in clinical practice than in the clinical trial.
An economic evaluation also demands a translation of the gain
in median PFS to gain in mean OS, adjusted for quality of life,
in order to provide an estimate of the gain in quality-adjusted
life years (QALY). The extrapolation from median to mean sur-
vival requires estimating the entire survival curve, rather than
only the portion above 50%. The tail of the curve often cannot
be observed directly, and since it contains observations with long
survival and thus a large impact on the mean, estimates of mean
survival tend to be uncertain. The adjustment for quality of life has
two effects. It incorporates gains in quality of life from increas-
ing the time to progression, but also reduces the value of gains in
survival that are spent in states with less than full quality of life
(Fig. 2).
Economic evaluations draw upon data from a variety of sources:
clinical, epidemiologic, and economic, and the uncertainty around
the estimates of cost-effectiveness are often large. It is thus not
surprising that there are controversies around both data and
methodology for such studies. Since decisions have to be made, the
issue is not about the level of uncertainty of the result, but rather
if decisions can be improved with, rather than without, economic
evaluations.
A review of the cost-effectiveness studies of sunitinib can illus-
trate the challenges of undertaking cost-effectiveness studies, and
the conclusions that have been made [13]. The reviewed studies
were published during 2007–2011, including ﬁve full text articles,
24 research abstracts and one HTA report.
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Table 1
New  targeted drugs for mRCC.
Drug FDA approval EMA approval Improvement in PSFa Comments
Soraﬁnib 2005 2006 PFS compared with IFNa (5.7 versus 5.6 months)
when used ﬁrst-lineb Second line after failure of
IFNa median PFS (5.5 versus. 2.8 months)
Liver cancer Orphan drug
Sunitinib 2006 2006 PFS versus INF (11versus 5 months) Also GIST
Temsirolimus  2007 2007 PFS versus INF (3.8 versus 1.9 months) Iv adm. And lymphoma Orphan drug
Bevacizumab 2009 (RCC) 2009 (RCC) PFS versus INF (10.2 versus 5.4 months) Iv adm. Several other indications
Pazopanib 2009 2009 PFS versus INF (9.2 versus 4.2 months)
Everolimus 2009 2009 PFS (4.9 versus 1.9 months) Also breast and pancreas cancer second line
Axitinib  2012 2012 PFS versus soraﬁnib (6.7 versus 4.7 months) Second line only in mRCC. In EU only post
sunitinib/or interleukin
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b [10].
Nearly all studies used a Markov model that simulated disease
rogression and determined survival and costs for a hypothetical
ohort of mRCC patients. The cost-effectiveness models included
hree or four mutually exclusive health states, among which
atients transition, during the modelled time horizon: ﬁrst line
ntil progression, second line treatment, best supportive care (BSC)
nd death (due to cancer or other causes).
Out of the 20 congress abstracts concerning ﬁrst-line mRCC
reatment, 16 were based on a same model or similar model struc-
ure presented in more detail in the full articles [14–16].
All  the articles (n = 5) were either sponsored by pharmaceutical
ndustry or at least one of the authors was an employee of a phar-
aceutical company; this was also the case in nearly all abstracts
21 out of 24).
Incremental cost-effectiveness ratios for ﬁrst-line sunitinib
anged from D 4786 to 109,416/QALY and D 33,807 to 100,212/life-
ear gained (LYG) when compared with IFN-alpha. An important
river of cost-effectiveness was the assumption about which drug
as used in second line treatment.
Does the review provide practical guidance for decisions based
n cost-effectiveness? The answer to this question must be “no”.
ecause of uncertainty in the clinical data, the key questions
bout how sunitinib effects costs and outcome in terms of (qual-
ty adjusted) life years gained is not answered in an unequivocal
ay. The conclusion, that in most of the reviewed studies sunitinib
ives a reasonable cost per QALY is not very helpful. An alternative
onclusion could be that the cost-effectiveness studies of sunitinib
o not provide clear guidance to help guide use. Thus we cannot
xpect that those studies have a signiﬁcant impact on uptake and
se. Given lack of direct data estimating OS and quality of life, at
ig. 2. Present standard of care gives 6 month until progression and 14 moths from
rogression to death. Quality of life is 0.78 until progression and 0.70 after progres-
ion. The total QALY is 0.78 * 6/12 + 0.70 * 14/12 = 0.39 + 0.83 = 1.22 QALY. OS is 20
onths. New therapy extend the time to progression until 18 months, followed by
 month in progression until death. OS is increased to 26 months (0.5 LYG). When
he survival gain is adjusted for QoL the gain is 0.35. To this should be added the QoL
mprovement from a longer time before progression, 12 months at a difference of
.08, gives 0.08 QALY. Total gain is 0.43 QALY. The total QALY with the new treatment
s  18 * 0.78/12 + 8 * 0.70/12 = 1.17 + 0.47 = 1.64 QALY.the price asked, the cost-effectiveness is at best questionable, and
thus consistent with both positive and negative decisions.
Several economic studies were developed by/for the phar-
maceutical industry based on the same cost-effectiveness model
for several jurisdictions. Often, the adaptation to different coun-
tries simply redeﬁned the resource use and unit cost information.
Because the underlying structure is the same in all cases, and the
data on factors most inﬂuencing the outcome—the beneﬁt of suni-
tinib on OS and QoL—is lacking, the large number of studies does
not necessarily increase the power of evidence.
Information on the use of healthcare resources may be obtained
with different methods and from various sources (e.g., expert opin-
ion, registers, local patients and literature). The estimates can often
be very important for the result of economic evaluations. For exam-
ple, in an article by Remák et al., the cost of best supportive care
(BSC) was one of the most sensitive parameters in the analysis and
a 20% reduction in its cost doubled the incremental costs per QALY
gained [16]. Lack of adequate information on resource use and costs,
limited clinical evidence and short follow-up times present major
challenges for performing timely economic evaluations of novel
cancer treatments.
In  essence, there only exist two  studies of the cost-effectiveness
of sunitinib, the company study PenTAG and the HTA study used
for the NICE technology appraisal [11]. Estimates from the PenTAG
model suggested that none of the interventions would be con-
sidered cost-effective at a willingness-to-pay threshold of 30,000
pounds per quality-adjusted life-year (QALY). Estimates of cost per
QALY ranged from 71,462 pounds for sunitinib to 171,301 pounds
for bevacizumab plus IFN. Although there are many similarities in
the methodology and structural assumptions employed by PenTAG
and the manufacturers of the interventions, in all cases the cost-
effectiveness estimates from the PenTAG model were higher than
those presented in the manufacturers’ submissions.
Coverage decisions for new therapies for mRCC
Despite the many problems involved in providing relevant esti-
mates of the cost-effectiveness of the new, targeted therapies in
mRCC, such studies are used as a basis for decisions about value for
money in coverage decisions. Since there in most cases are no pub-
lished economic studies to rely on when the product comes to the
market, decisions are based on studies undertaken by the company
or by the reimbursement agency itself.
NICE has well-developed methods and processes for under-
taking economic evaluation for decisions about use of a drug by
NHS (the National Health Service) in England and Wales. Sunitinib
was recommended in 2009 as a ﬁrst-line treatment option for
people with advanced and/or metastatic renal cell carcinoma who
are suitable for immunotherapy and have an Eastern Cooperative
Oncology Group (ECOG) performance status of 0 or 1 [17]. The
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ecommendation includes the condition that the company pro-
ides the drug for the ﬁrst cycle free of charge. This provided two
eneﬁts in the light of the uncertainty about cost-effectiveness: it
s a hedge against the possibility that the true cost-effectiveness
f sunitinib is less favourable than estimated and it provides a
ow-cost mechanism to get better information during the initial
hase of treatment regarding who would respond and who would
ot respond (presumably those who don’t respond in the ﬁrst
onth will not receive further doses).
In addition to its guidance on sunitinib stated above, another
ICE guidance in 2009 recommended against the use of beva-
izumab, sorafenib and temsirolimus as ﬁrst-line treatment options
or people with advanced and/or metastatic renal cell carcinoma
18]. Sorafenib and sunitinib are not recommended as second-
ine treatment options for people with advanced and/or metastatic
enal cell carcinoma.
Pazopanib was recommended by NICE in 2011 as a ﬁrst-line
reatment option for people with advanced renal cell carcinoma
ho have not received prior cytokine therapy and have an Eastern
ooperative Oncology Group (ECOG) performance status of 0 or 1
nd if the manufacturer provides pazopanib with a 12.5% discount
n the list price, and provides a possible future rebate linked to
he outcome of the head-to-head COMPARZ trial (Pazopanib versus
unitinib in Metastatic Renal-Cell Carcinoma), as agreed under the
erms of the patient access scheme and to be conﬁrmed when the
OMPARZ trial data are made available [19].
Since 2003, most Canadian provinces have participated in the
ommon Drug Review (CDR), which assesses the clinical and cost-
ffectiveness of oral agents according to standardized methods.
ince 2009, most provinces have also participated in the Joint
ncology Drug Review (iJODR), since 2011 replaced by pCODR
www.pCODR.ca). The assessment of soraﬁnib by Canadian Expert
rug Advisory Committee (CEDAC) of the CDR, illustrates the use
f economic evaluation when the ﬁrst target drug for mRCC came
o the market [20].
The  submission in Canada for soraﬁnib from the drug’s manu-
acturer used a Markov model, with key parameter estimates based
n the TARGET trial (Treatment Approaches in Renal Cancer Global
valuation Trial), which studied soraﬁnib second line after failure
f INFalpha. This model estimate transition probabilities based on
he data observed in the trial from PFS to progressive disease or
eath up until the point of cross-over. The model estimated a dif-
erence in overall survival (over a lifetime) of 1.21 years and an
ncremental cost per life-year gained of $36,046. In its assessment
f the evidence, the CDR concluded that, given the early termi-
ation of the trial, the overall survival advantage, and hence the
rue cost-effectiveness of sorafenib, were uncertain. Rather than
ccepting the manufacturer’s projections, it conducted its own
nalysis, which assumed that once patients entered the progres-
ive disease state, being treated with sorafenib had no further
mpact on survival. The CDR analysis generated an estimate of over-
ll survival gain of 4.5 months, which was closer to that actually
bserved in the trial at the time of the most recent analysis of
utcome. Using this revised estimate of survival gain, the incre-
ental cost-effectiveness ratio rose to $78,227, more than twice
he manufacturer’s estimate. Consequently, CEDAC recommended
hat sorafenib not be listed.
In  2012 pCODR recommended axitinib for use second line for
atients that could not tolerate everolimus. Soraﬁnib was  no longer
onsidered a relevant alternative due to lack of data on effective-
ess after sunitinib. In 2013 pazopanib was recommended for ﬁrst
ine use based on a comparison with sunitinib; similar effectiveness
nd lower price [21].
In  Sweden TLV is assessing prescription drugs for inclusion in
he reimbursement scheme. Both sorafenib and sunitinib were
ccepted for reimbursement on the clinical and economic dataer Policy 2 (2014) 12–21 15
provided  by the company. In the decision about sunitinib, some
members of the Board did not agree, and asked for more informa-
tion about cost-effectiveness [22,23]. For everolimus TLV accepted
reimbursement for second line treatment of mRCC [24]. TLV
accepted the economic model provided by the company, which
estimated a cost per QALY of 285,000 SEK (30,000 Euro) for
everolimus compared with soraﬁnib. This indirect comparison was
accepted since soraﬁnib was the most used therapy for this group
of patients, despite no evidence of its effectiveness after failure of
sunitinib.
In the US, cost-effectiveness analyses are not used to make
yes/no funding decisions regarding particular cancer drugs as they
are in Europe and Canada. In fact, laws enacted nationally for
Medicare enrolees (adults ages 65 and greater) and in most states
(affecting commercial insurance plans) mandate coverage of can-
cer drugs listed as safe and effective according to at least one
nationally-recognized compendia or clinical practice guideline (for
example, the National Comprehensive Cancer Network). What can
vary, however, is the co-pay amount that is levied on speciﬁc drugs.
The process for determining co-pays can vary widely from insurer
to insurer. At one extreme is Premera Blue Cross, a regional insurer
in the Paciﬁc Northwest that sets co-pays for new oral cancer drug
based on the estimated cost-effectiveness of the therapy relative to
the best available alternative. Intermediate are “value based formu-
laries” that use some combination of clinical and economic efﬁcacy
to determine co-pay levels. At the other, perhaps more common,
extreme are plans that base co-pays on (branded) drug price alone.
Thus, in the US all FDA-approved drugs are generally available, and
there are few barriers to prescribing them. The very high cost of
these new targeted agents, however, means that high co-payments
can effectively exclude access to the drug from large segments of
the population. To the extent that even modest co-pays can lead to
substantial out-of-pocket costs, several studies now suggest that
ﬁnancial distress and bankruptcy are increasingly common prob-
lems for cancer patients and their families [25–27].
Uptake and use of new drugs for mRCC
The ﬁgures below present the use of sorafenib, sunitinib and
temsirolimus in selected countries 2005–2009. Please note that
soraﬁnib is also approved for primary liver cell cancer (Fig. 3).
The  most striking result is the very low uptake and use in the UK
and the US. France has the highest use, while Germany, Italy and
Spain are all rather close to a western EU average. For Switzerland
we see a rapid uptake, and then a decline, which may  be depen-
dent on substitution with sunitinib or other drugs. The low use of
sorafenib in the US may  be related to the fact that sunitinib was
available ﬁrst, and that phase II study data for sorafenib at launch
did not show an increase in PFS with sorafenib compared with IFNa
(5.7 versus 5.6 months) when used ﬁrst-line, making its role in
therapy of untreated patients unclear [10] (Fig. 4).
For  sunitinib we see the same fast and high uptake in France, and
that Germany here is close to France. Use in Switzerland relatively
lower than for sorafenib. UK is in the lower end, but the difference
to other countries is small. For US we  see a rapid uptake, and then
a plateau from 2007 onwards.
France  stands out in terms of a more rapid uptake and higher
use. With the exception of US and Italy, the use is very marginal
until Q2 2009 (Fig. 5).
The  low use in UK is supported by data in the report by Mike
Richards [28]. According to table A6 in the report the UK usage
was 19 and 54 percent of the average use in the 5 big European
countries for soraﬁnib and sunitinib respectivly for the period April
2008 to March 2009. For temsirolimus the UK useage was 17%. Fig. 6
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Fig. 3. Use of soraﬁnib in mg per 100,000 population.
Fig. 4. Use of sunitinib in mg per 100,000 population.
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Fig. 5. Use of temsirolimus in mg  per 100,000 population.
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weden.
Fig. 7 shows the variations within Sweden, indicating signiﬁcant
ariations, both in the use of the individual drugs and the use of all
rugs combined. More detailed data on use in ﬁrst line versus sec-
nd line, and about patient characteristics are necessary in order to
nderstand the magnitude of potential under- and overconsump-
ion in different regions/patient populations.
opulation evidence of impact of TKIs of outcome
We  have identiﬁed ﬁve studies that examined the effects on
urvival from the use of targeted therapies in advanced RCC patients
utside of trial settings.
Shah  et al. analyzed the Surveillance, Epidemiology, and End
esults (SEER) 18 registry database to compare 1- and 3-year
elative survival rates among advanced RCC patients during
001–2009, 2001–2004, and 2006–2009, the 1-year relative sur-
ival rates were 27.0 ± 0.8% and 27.1 ± 0.9%, (p value = 1.3) and, the
-year survival were 10.1 ± 0.6% and 9.6 ± 0.8%, (p value = 1.42),
uring 2001–2004 and 2006–2009, respectively. Thus, this pop-
lation based study suggested that there was no signiﬁcant
mprovement in relative survival rates among mRCC patients in
he era of targeted agents [29].
In another study from the US, Shek et al. analyzed data
rom 28,252 patients with RCC in the California Cancer Registry
CCR), a population-based cancer surveillance system, diagnosed
etween 1998 and 2007 [30]. Inter-era differences in clinical
ariables—including year of diagnosis, histologic characteristics,
ge, sex, race, stage, nephrectomy status, overall survival (OS),
nd cause-speciﬁc survival (CSS)—were assessed, and analyzed
ith univariate and multivariate Cox models. Crude 3-year OS68.2% vs. 74.6%; 2P .001) and CSS (78.1% vs. 82.3%; 2P .001)
ere signiﬁcantly higher in the post-cytokine era. The three
trongest predictors for improved survival were localized disease,
ephrectomy and histologic type. Insufﬁcient follow-up time inealth care regions of Sweden 2011.
the post-cytokine era and a higher proportion of localized dis-
ease in that era confound the possibility of beneﬁt derived from
targeted therapies. Longer follow-up for patients treated in the
post-cytokine era is necessary for a more robust comparison of
long-term OS.
In  a third US overall survival (OS) analysis, the analytic cohort
included all patients in the registry diagnosed between January 1,
2007, to May  31, 2011 [31]. Patients were grouped by up to three
treatment exposures according to each drug’s mechanism of action:
vascular endothelial growth factor tyrosine kinase inhibitor (VEGFR
TKI), mammalian target of rapamicin inhibitor (mTOR), or no sys-
temic treatment (NSTx, which could include radiation or surgery).
OS by exposure sequence was  evaluated using Kaplan–Meier, pair-
wise comparison, and Cox regression analyses. Median OS was
17.2 months. OS (months) for one exposure was: mTOR  5.4, TKI
18.2, NSTx 18.4; for two exposures: mTOR/TKI 9.3, TKI/mTOR
13.9, TKI/TKI 35.2; and for three exposures: TKI/mTOR/TKI 20.9,
TKI/TKI/mTOR 33.1. In Cox regression analysis, compared with the
referent (TKI), TKI/TKI (hazard ratio 0.53) had a lower risk of death,
and mTOR (hazard ratio 2.16) had a higher risk of death. The study
concludes that mRCC survival outcomes are different by pattern,
with general ﬁndings consistent with trial-based expectations in
similar patient populations. Real-world data can provide context
around patterns of care and impact when experimental trial data
are lacking.
Swedish researchers conducted a retrospective register study
assessed overall survival (OS) and inﬂuential factors on OS in
Swedish renal cell carcinoma (RCC) patients. They used three
merged national health registers to assess the impact of cytokine
(interferon- and tyrosine kinase inhibitor (TKI; sunitinib or
sorafenib) treatment on OS in metastatic mRCC. From 2000 to
2008, 8009 patients were diagnosed with RCC and 2753 with mRCC
(2002–2008). Median OS in RCC patients diagnosed from 2006 to
2008 compared with 2000–2005 was not reached vs. 47.9 months
(p < 0.001), and in mRCC patients diagnosed from 2006 to 2008
compared with 2002–2005, was 12.4 vs. 9.6 months respectively
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p = 0.004). Factors associated with signiﬁcantly improved OS in
CC were female gender, lower age, and previous nephrectomy,
nd, in mRCC female gender, previous nephrectomy, and any TKI
rescription (Model 1: median-adjusted OS, 19.4 months (TKI
atients) vs. 9.7 months (non-TKI patients); hazard ratio, 0.621;
 < 0.001). The results suggest that increased nephrectomy rates
nd the use of TKIs contributed to the improvement seen in mRCC
atients. However, it should be noted that only 12% of the patients
eceived a TKI in ﬁrst line treatment [32].
Soerensen et al. included all Danish patients with mRCC starting
rst line treatment with immunotherapy, TKIs or mTOR-inhibitors,
etween 2006 and 2010 in an outcome study. Baseline and outcome
ata were collected retro-spectively. Between 2006 and 2010, a
otal of 1073 patients were referred. Of these, 759 patients received
rst line treatment and 314 received no systemic treatment. The
roportion of treated patients increased from 64% in 2006 to 75%
n 2010 (p = 0.02). In 2006, 22% received targeted therapy and this
ncreased to 75% in 2010 (p < 0.00001). In 2006, 21% of ﬁrst line
atients received second line treatment compared to 41% in 2010
p = 0.01). From 2006 to 2010, we observed an improved median
S from 11.5 to 15.7 months (p = 0.03. The untreated population of
14 patients had a median OS of 3.1 months from date of metastatic
isease with no signiﬁcant change from 2006 to 2010 [33].
iscussion
This  paper reviews the link between clinical trial data, the
ost-effectiveness studies for new cancer drugs, coverage decisions
nformed by such studies, uptake and use of the drugs, and evidence
f impact on outcome in the relevant patient population.
The review of economic and clinical evaluations for new tar-
eted therapies for mRCC reveals that there are great uncertainties
n the estimates of cost-effectiveness, resulting in uncertain rele-
ance of these studies for decision making following launch. This
ncertainty is partly related to the methodological challenges mak-
ng extrapolation from clinical trial data to clinical practice, since
ll models used for estimating cost-effectiveness have to make
ssumptions to predict long term costs and outcome.
The choice of extrapolation methodology can have an important
mpact on comparative efﬁcacy, costs, and cost-effectiveness. This
as shown by Ekman et al. in the illustrative example using data
rom a pivotal phase III trial of sunitinib vs. IFN-a as ﬁrst-line mRCC
n the US. Cost effectiveness results could vary quite substantially
epending on assumptions made. A short time horizon (one year)
esulted in an ICER of $120,304 compared to an ICER of $52,571
or the life time horizon assumption. Depending on choice of sur-
ival distribution, ICERs varied between $50,000 and 150,000 the
essimistic (stop and drop) scenario and the optimistic (continued
eneﬁt) assumption resulted in large differences in ICERs; $114,000
s. $50,000, respectively [34].
Offering patients in oncology trials the opportunity to cross over
o active treatment at disease progression is a commonly used strat-
gy to address ethical issues associated with use of placebo controls,
ut may  lead to statistical challenges in the analysis of overall
urvival (OS) and cost-effectiveness as cross-over leads to loss of
nformation and dilution of comparative clinical efﬁcacy. This was
llustrated by comparing alternative methods for analysing OS data
n the presence of cross-over; simple methods (intent-to-treat anal-
sis and censoring data at cross-over) and advanced statistical
ethods (the inverse probability of censoring weighting [IPCW]
nd the rank-preserving structural failure time [RPSFT] models,
sing data from two phase III clinical oncology trials of sunitinib.
he study shows that the method for correction may  signiﬁcantly
ffect the cost-effectiveness ratio, while this was  not the case in
ICE assessment of sunitinib for mRCC. There the selection of a
opulation with no second line treatment was most important toer Policy 2 (2014) 12–21 19
bring the cost-effectiveness ratio below the 50,000 GBP per QALY
[35].
Statistical methods may  to some extent help to overcome the
problem that clinical studies for market authorization are not
designed to take into account the requirement for health technol-
ogy assessment. This problem may  be reduced with the increasing
use of HTA and parallel regulatory/HTA scientiﬁc advice during the
development process [36]. Progression free survival (PSF) as an
outcome measure is also increasingly questioned, also from a reg-
ulatory point of view [37]. However, PFS will remain an important
endpoint, which can be more useful as an input to estimations of
cost-effectiveness if it already at the start of the study is work out
how the measure of PFS is linked to OS and quality of life, the two
measures used for calculation of the gain in QALY. Reducing the use
of crossover is an important factor for improving the value of PFS
as an outcome measure [38].
Indirect comparisons play an important role in assessment
of cost-effectiveness. The assessment of relative effectiveness of
pazopanib by EuronetHTA provided no evidence on differences in
effectiveness between the different targeted therapies for mRCC
[39]. This conclusion was supported by the results of the direct
comparison between pazopanib and sunitinib [12].
With the exception of UK and Canada, there is no evidence
that cost-effectiveness estimates has played a key role for reim-
bursement and use of the new targeted therapies in mRCC. This
conclusion is supported from a study comparing the number of
reimbursed indications in different countries for a selection of can-
cer drugs [40]. Most indications were reimbursed in other countries
than UK, Canada, Australia and New Zealand.
From one perspective, it is not surprising that formal cost-
effectiveness estimate have a limited impact on decisions to
reimburse or not reimburse, since the uncertainty surrounding the
ICERs is high. On the other hand, decision makers may use the data
and the models in these studies to call for restrictions in use while
further data are gathered e.g., in the context of an observational
study or a pragmatic trial. Value of information analysis can be
used to determine whether the investment in further study will
yield sufﬁcient reductions in uncertainty to warrant the cost and
delay in access entailed in another trial. There are also examples
that cost-effectiveness studies are used as a basis for market access
agreements including reductions in the prise of the drugs.
While  it is possible to notice an impact of the cost-effectiveness
ratio on the probability of a positive reimbursement decisions, it is
seldom possible to assess the relative contribution in an individual
decision. One reason for this is that evidence on clinical efﬁcacy, the
probably most important factor for reimbursement, is correlated
to estimates of effectiveness, and thus cost-effectiveness. It is also
easier to see that cost-effectiveness has an impact when there is a
choice between two  drugs with similar effectiveness, such as the
case with sunitinib and pazopanib for ﬁrst line treatment of mRCC.
Prices will then be the key determinant of cost-effectiveness, and
since prices can easily be changed, the impact of cost-effectiveness
should be assessed based on data on use, rather than decisions on
reimbursement.
Worldwide, economic evaluations appear to have had little
impact on the diffusion of targeted therapies into practice. Data on
international variations in use indicate that other factors, mainly
from the supply side, account for most of the variation. The most
important demand side factor is the economic power of the coun-
try, measured as income or health care expenditures per capita.
Since prices of new drugs vary less than per capita income, it may
be interpreted as linked to the cost-effectiveness, as well as the
affordability, of new drugs in countries with low per capita income.
Data also indicate that how the drugs are paid for in the health care
system is important. The high use in France can be explained by
the practice of making price volume agreements; in combination
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ith reimbursing the hospitals for the cost of new drugs outside
he DRG based hospital funding.
Our review of available studies of impact on survival for patients
ith mRCC indicates that there may  be an effect, but the magnitude
s uncertain. The problems to detect an effect in epidemiological
ata suggest that the effect is small, and a deﬁnitive conclusion
s hampered by patient selection issues that cannot be resolved
ith available data. Further studies are needed to give information
n how the new targeted therapies should be optimally used in
ractice. Questions about optimal use of the drugs in parallel or
equence can be answered with information from data in clinical
ractice.
onclusions and policy recommendations
The value of new cancer therapies is based on their use. To
chieve an optimal use there are several steps from the initial eco-
omic evaluations based on clinical trial data, the reimbursement
coverage) decisions based on these data, and the implementation
f these decisions in clinical practice.
Considerable resources have been devoted to the study of cost-
ffectiveness of new cancer drugs as a basis for decisions about
ayment and use. Those resources could be much better used if
ndustry and HTA agencies with high competence collaborated at an
arly stage. That would increase both the quality and the credibil-
ty of studies, and make them more useful to guide decisions about
eimbursement. The methodology for studies has been debated,
nd there are opportunities for improvement. Most important
rom a general methodological point of view is that all costs are
ccounted for and that the beneﬁt measure incorporates all ele-
ents of social value. While there is a discussion if the QALY
ncludes all relevant elements of value, there is an acceptance
rom all stakeholders that estimations of cost per QALY are rele-
ant for decisions about coverage. Since improvements in survival
or cancer patient, it is important that cost per LYG also is calcu-
ated and presented in parallel to the cost per QALY. There is also
 need for improvements in data used for calculating the QALY
ains.
A major problem is when the clinical trial data do not provide
lear evidence on outcome, for example due to the use of surrogate
nd-points and crossover design in the study. Statistical methods
or extrapolation may  to some extend help to overcome this prob-
em, but it is important that clinical studies are decided taking into
ccount the requirement for health technology assessment. The
raditional trial methodology with PSF and crossover has serious
hortcomings, when the data should be used for assessment of cost-
ffectiveness, and there is a need for a new standard. Guidelines for
his new standard should be developed in collaboration between
egulatory and HTA authorities.
Indirect  comparisons are often necessary for assessment of cost-
ffectiveness. It is not possible to undertake clinical trials for all
otentially relevant alternatives in clinical practice. A limitation
f all indirect comparisons is that they are based on trial data.
he options for using observational studies in clinical practice to
nswer questions about alternative treatment strategies should be
ssessed as early as possible. Such studies should be combined with
ata collection for assessment of relative efﬁcacy and risk-beneﬁt,
nitiated directly after marketing authorization.
A closer link between studies, decisions about coverage and the
ctual allocation of resources for new drugs is also needed. The data
or studies of the implementation of reimbursement decisions are
carce, and available evidence indicates that there is a gap between
ecisions and implementation, resulting in an inefﬁcient use of new
rugs and thus a loss of value. Linking economic incentives, such as
ay for performance is one way to close this gap.
[er Policy 2 (2014) 12–21
Economic evaluations and coverage decisions are based on
uncertain data, and thus the impact on outcome in clinical prac-
tice is uncertain. It is therefore necessary to collect data on actual
use in to make it possible to study the effects on outcome in clinical
practice. Since outcome depends on a number of factors, individ-
ual patient data are a necessary requirement for revealing impact
on outcome. Such data may  also help to inform decisions in clini-
cal practice which are not, and often cannot, be informed by clinical
trial data; for example the cost and outcome of use of drugs in com-
bination and/or sequence. These data must include not only drug
therapies but also all relevant diagnostic and therapeutic interven-
tions, which are important for optimizing and revealing the value
of new the drugs in clinical practice.
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